Exciting Explosion of New Drugs In CLL

Speaking to the European Medical Journal at the EHA2014 meeting, Prof John Gribben, St Barts Hospital, London, UK, outlines the explosion of new drugs now available for patients based on the increased understanding of CLL disease biology.  He outlines the efficacy and safety results from the RESONATE trial with ibrutinib versus Ofatumumab, idelalisib versus rituximab monotherapy study, and data with ABT-199 as monotherapy and in combination with obinutuzumab/GA101.  Prof Gribben also comments on resistance observed with ibrutinib.

Year of Production:
Running Time:


Comments are closed.